Search

AstraZeneca PLC

Cerrado

Sector Salud

11,646 -0.7

Resumen

Variación precio

24h

Actual

Mínimo

11506

Máximo

11702

Métricas clave

By Trading Economics

Ingresos

-498M

1.4B

Ventas

632M

14B

P/B

Media del Sector

37.64

59.362

BPA

2.08

Rentabilidad por dividendo

2.016

Margen de beneficio

10.531

EBITDA

548M

4.7B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+13.97 upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.02%

2.35%

Próximas Ganancias

29 abr 2025

Fecha Próximo Dividendo

24 mar 2025

Próxima Fecha de Ex Dividendo

20 feb 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

176B

Apertura anterior

11646.7

Cierre anterior

11646

Noticias sobre sentimiento de mercado

By Acuity

44%

56%

170 / 393 Clasificación en Healthcare

AstraZeneca PLC Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

6 feb 2025, 11:07 UTC

Ganancias

AstraZeneca Expects Revenue, Earnings Growth Despite Sales Drop in China -- Update

6 feb 2025, 07:27 UTC

Ganancias

AstraZeneca Expects Further Sales, Earnings Growth After Results Beat Market Views

24 dic 2024, 15:24 UTC

Adquisiciones, fusiones, absorciones

Achilles Therapeutics Sells Technology Assets to AstraZeneca for $12 Million

12 nov 2024, 19:55 UTC

Ganancias

AstraZeneca Expands U.S. Investment Plan -- 3rd Update

7 feb 2025, 10:30 UTC

Principales Noticias

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 feb 2025, 15:18 UTC

Charlas de Mercado

U.K. Health System Needs to Improve Investment Environment, AstraZeneca CEO Says -- Market Talk

6 feb 2025, 13:24 UTC

Charlas de Mercado

AstraZeneca's Increased R&D Spend Is a Positive -- Market Talk

6 feb 2025, 12:01 UTC

Ganancias

Global Stocks in Spotlight: BYD, Kering, Maersk -- WSJ

6 feb 2025, 11:22 UTC

Charlas de Mercado
Ganancias

AstraZeneca's Sales Beat, Pipeline Outshines Margin Miss -- Market Talk

6 feb 2025, 11:18 UTC

Charlas de Mercado
Ganancias

AstraZeneca's Outlook Makes Midterm Target Look Achievable -- Market Talk

6 feb 2025, 11:02 UTC

Charlas de Mercado
Ganancias

AstraZeneca's China Woes Seem Manageable -- Market Talk

6 feb 2025, 07:02 UTC

Ganancias

AstraZeneca Declares Dividend $3.10

6 feb 2025, 07:01 UTC

Ganancias

AstraZeneca Sees 2025 Core EPS Increase By Low Double-Digit Percentage At Constant Currency

6 feb 2025, 07:01 UTC

Ganancias

AstraZeneca Sees 2025 Total Rev Increase By High Single-Digit Percentage At Constant Currency

6 feb 2025, 07:00 UTC

Ganancias

AstraZeneca Issues 2025 View

6 feb 2025, 07:00 UTC

Ganancias

Analysts Saw AstraZeneca 4Q Rev $14.2B

6 feb 2025, 07:00 UTC

Ganancias

Analysts Saw AstraZeneca 4Q Core EPS at $2.07

6 feb 2025, 07:00 UTC

Ganancias

AstraZeneca PLC 4Q EPS 96c

6 feb 2025, 07:00 UTC

Ganancias

AstraZeneca PLC 4Q Adj EPS $2.09

6 feb 2025, 07:00 UTC

Ganancias

AstraZeneca PLC 4Q Net Pft $1.5B

6 feb 2025, 07:00 UTC

Ganancias

AstraZeneca PLC 4Q Rev $14.89B

6 feb 2025, 07:00 UTC

Ganancias

AstraZeneca PLC 4Q Pretax Pft $1.67B

6 feb 2025, 07:00 UTC

Ganancias

AstraZeneca PLC 4Q Oper Pft $2.04B

29 ene 2025, 16:56 UTC

Principales Noticias

RFK Jr. Hearing Kicks Off With Nomination Under Fire -- Barrons.com

29 ene 2025, 15:14 UTC

Principales Noticias

RFK Jr. Hearing Kicks Off With Nomination Under Fire -- Barrons.com

20 ene 2025, 08:02 UTC

Charlas de Mercado

AstraZeneca Trial Results In Focus Amid China Sales Concerns -- Market Talk

18 nov 2024, 10:33 UTC

Charlas de Mercado

Pharmaceutical Sector Outlook for 2025 Looks Rocky -- Market Talk

15 nov 2024, 13:08 UTC

Principales Noticias

Trump's RFK Pick Weighs on Vaccine Makers -- WSJ

15 nov 2024, 10:29 UTC

Acciones populares

Stocks to Watch Friday: Tesla, Domino's, Palantir, Ulta -- WSJ

12 nov 2024, 15:30 UTC

Principales Noticias

AstraZeneca Expands U.S. Investment Plan -- 2nd Update

AstraZeneca PLC Esperado

Precio Objetivo

By TipRanks

13.97% repunte

Estimación a 12 meses

Media 13,354.55 GBX  13.97%

Máximo 19,000 GBX

Mínimo 10,500 GBX

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AstraZeneca PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

13 ratings

8

Comprar

5

Mantener

0

Vender

Sentimiento

By Acuity

170 / 393 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.